AMLX jumps on Phase 3 LUCIDITY avexitide topline results
ALXN-backed ally?—No: AMLX is up about 29% after positive topline results from the Phase 3 LUCIDITY clinical trial of avexitide, while HAE and BBWI also post gains and HD adds a 2% earnings move.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.